Tekes Finances Biotie's Thrombosis Program With EUR 1.7 Million

Turku, Finland, Jan 7, 2008 - (Hugin via ABN Newswire) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 January, 2008

TEKES FINANCES BIOTIE'S THROMBOSIS PROGRAM WITH EUR 1.7 MILLION

The Finnish Funding Agency for Technology and Innovation (Tekes) has granted EUR 1.7 million additional funding for Biotie Therapies' integrin alpha2beta1 inhibitor program for thrombosis. The R&D funding granted covers drug development costs of the project from July 2007 to December 2009.

The funding granted is in the form of loan and it covers 50 per cent of the costs of the project. The loan will be paid to Biotie against reported realised costs. In order to receive the full amount of granted financing, Biotie must show a total expenditure of EUR 3.4 million in the project.

Turku, 7 January 2008

Biotie Therapies Corp.

Timo Veromaa President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com

www.biotie.com

Distribution: OMX Nordic Exchange Helsinki Main Media

Copyright © Hugin ASA 2008. All rights reserved.

Biotie Therapies Oyj

http://www.biotie.com

ISIN: FI0009011571

Stock Identifier: XHEL.BTH